Global Beta-Thalassemia Market – Industry Trends and Forecast to 2030

베타 지중해 빈혈 시장 분석 및 규모

지중해 빈혈 유병률의 증가는 시장 성장 확대로 이어질 주요 원동력으로 작용할 것입니다. 글로벌 베타 지중해 빈혈 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 의료비 지출 증가입니다. 나아가 의료 기술의 발전, 공공 및 민간 기관의 인식 확산을 위한 이니셔티브 증가, 정부 자금 지원 증가는 글로벌 베타 지중해 빈혈 시장을 확대할 요인입니다. 또한, 높은 가처분 소득과 변화하는 라이프스타일은 글로벌 베타 지중해 빈혈 시장의 확대로 이어질 것입니다.

 Data Bridge Market Research는 2022년에 83억 2천만 달러였던 글로벌 베타 지중해 빈혈 시장이 2030년까지 112억 2천만 달러에 도달할 것으로 예상되며, 2023년에서 2030년까지의 예측 기간 동안 8.0%의 CAGR을 보일 것으로 분석했습니다. "베타 지중해 빈혈 경증"은 지중해 빈혈의 유병률이 증가함에 따라 글로벌 베타 지중해 빈혈 시장의 유형 세그먼트를 지배하고 있습니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

베타 지중해 빈혈 시장 범위 및 세분화

시장 정의

베타 지중해 빈혈은 혈액 질환의 한 유형입니다. 이것은 신체가 정상보다 적은 헤모글로빈을 생성하는 유전적 상태입니다. 헤모글로빈은 적혈구에 존재하는 철분 함유 단백질을 말하며, 신체 전체의 세포로 산소를 운반하는 것을 포함합니다. 헤모글로빈 수치가 낮으면 신체의 여러 부위에서 산소가 부족해집니다. 베타 지중해 빈혈은 HBB 유전자의 돌연변이로 인해 발생합니다. HBB 유전자는 베타 글로빈이라는 단백질을 생성하기 위한 지침을 전달합니다. 이 상태는 빈혈, 호흡 곤란, 피로, 빠른 심장 박동, 기분 변덕, 황달 및 느린 성장 등이 특징입니다. 지중해 빈혈은 베타 지중해 빈혈의 또 다른 용어입니다.

글로벌 베타 지중해 빈혈 시장 동향

운전자

• 탈레세미아 유병률 증가

지중해 빈혈의 증가하는 유병률은 글로벌 베타 지중해 빈혈 시장에서 중요한 원동력으로 작용합니다. 비정상적인 헤모글로빈 생성을 특징으로 하는 유전적 혈액 질환인 지중해 빈혈은 전 세계적으로 상당수의 개인에게 영향을 미칩니다. 지중해 빈혈의 증가하는 유병률은 혈액 수혈, 킬레이션 요법,  유전자 요법 및 줄기 세포 이식과 같은 잠재적으로 치유 가능한 치료법을 포함한 의료 개입이 필요한 환자 집단을 증가시킵니다. 이러한 증가하는 환자 풀은 글로벌 베타 지중해 빈혈 시장에서 진단 검사 , 치료제 및 지지 치료  에 대한 수요를 촉진 하여 혁신적인 치료 옵션의 연구, 개발 및 상용화 기회로 이어집니다.

• 증가하는 의료비 지출

Rising healthcare expenditure acts as a significant driver in the global beta-thalassemia market. The complex nature of thalassemia requires comprehensive medical management, including regular blood transfusions, iron chelation therapy, and potential curative treatments. As the prevalence of thalassemia increases, healthcare expenditure on diagnostic tests, treatments, and supportive care rises accordingly. This drives the demand for advanced medical technologies, pharmaceuticals, and specialized healthcare services. Consequently, healthcare providers, research institutions, and pharmaceutical companies invest in developing innovative therapies, gene therapies, and supportive care options, driving market growth and contributing to improved outcomes for patients with beta-thalassemia.

Opportunities

• Increasing Advancements in Medical Technology

Advancements in medical technology present significant opportunities in the global beta-thalassemia market. Innovations in diagnostic tools, such as genetic testing and molecular techniques, enable early and accurate diagnosis of thalassemia. In addition, advancements in medical devices, such as portable infusion pumps for chelation therapy and implantable devices for monitoring iron levels, enhance treatment convenience and patient outcomes. Furthermore, gene therapy and stem cell transplantation technologies hold promising potential for curative treatments in beta-thalassemia. These advancements not only improve patient care but also create opportunities for research, development, and commercialization of cutting-edge therapies and medical devices in the global beta-thalassemia market.

• Increasing Demand for Precision Medicines

Advancements in genomics and precision medicine offer opportunities for tailoring treatments to individual patients based on their genetic profiles. This can potentially lead to more effective and targeted therapies for beta thalassemia.

Restraints/ Challenges

• Strict Regulations and Guidelines

The development and approval of new therapies for beta thalassemia can be a lengthy and expensive process due to stringent regulatory requirements. Companies may face hurdles in getting their products to market.

• Limited Treatment Options

There was a limited number of approved treatments for beta thalassemia, primarily involving blood transfusions and iron chelation therapy. The development of new and more effective treatments may face challenges related to research and regulatory approvals.

• High Cost of Treatment

The high cost associated with the treatment of beta-thalassemia poses a significant challenge in the global market. The complex management of beta-thalassemia, including regular blood transfusions, chelation therapy, and potentially curative treatments, involves substantial healthcare expenditures. The cost of specialized medications, supportive care, diagnostic tests, and lifelong management can place a financial burden on patients, healthcare systems, and payers. This challenge limits accessibility to optimal care, particularly in regions with limited healthcare resources and individuals without adequate insurance coverage. Addressing the high cost of treatment is crucial to ensure equitable access and improve outcomes for patients with beta-thalassemia worldwide.

This global beta-thalassemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the global beta-thalassemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Global Beta Thalassemia Market Scope

The global beta-thalassemia market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.   

Type

• Beta Thalassemia Minor
• Beta Thalassemia Intermedia 
• Beta Thalassemia Major

Treatment

• Iron Chelating Drugs
• Erythroid Maturation Agents
• Stem Cell Therapy
• Blood transfusion
• Others

 Diagnosis

• Complete Blood Count (CBC)
• Hemoglobin Electrophoresis with Hemoglobin F and A2 Quantitation
• Others

Symptoms

• Shortness of Breath
• Tiredness
• Fast Heartbeat
• Moodiness
• Jaundice
• Slow Growth
• Others

Dosage

• Injection
• Tablets
• Others

 Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospital
• Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Beta Thalassemia Market Regional Analysis/Insights

The global beta-thalassemia market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.     

The countries covered in the global beta-thalassemia market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.   

North America dominates the global beta-thalassemia market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of thalassemia and rising number of research activities in this region.  Asia-Pacific is expected to witness significant growth in the global beta-thalassemia market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Global beta-thalassemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for global beta-thalassemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global beta-thalassemia market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Global Beta-Thalassemia Market Share Analysis

The global beta-thalassemia market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the global beta-thalassemia market.   

Some of the major players operating in the global beta-thalassemia market are:  

• bluebird bio, Inc. (U.S.)
• Protagonist Therapeutics Inc. (U.S.)
• Agios, Inc. (U.S.)
• Ionis Pharmaceuticals (U.S.)
• Vifor Pharma Group (Switzerland)
• Sangamo Therapeutics (U.S.)
• CRISPR Therapeutics (Switzerland)

SKU-67632